MS4A1 and multiple sclerosis: Over time, new anti-CD20 monoclonal antibodies, such as ofatumumab (OFA), a fully human antibody that first used as disease-modifying therapies for multiple sclerosis [16], recognizes an epitope encompassing the small and large extracellular loops of CD20 receptors and has more efficient complement-dependent cytotoxicity in vitro [17].